Saiju Jacob

Employment

• The University of Birmingham

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (60)

• Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis
  Advances in Therapy 2026 DOI: 10.1007/s12325-026-03543-1
  +Save
• Frequent co-occurrence of AChR-positive myasthenia gravis in facioscapulohumeral muscular dystrophy suggests a novel disease association
  Journal of Neurology Neurosurgery and Psychiatry 2026 DOI: 10.1136/jnnp-2025-337550
  +Save
• Flipped and traditional classrooms in ophthalmology
  Eye Open 2025 DOI: 10.1038/s44440-025-00003-7
  +Save
• Autosomal recessive VWA1 -related disorder
  Brain Communications 2024 DOI: 10.1093/braincomms/fcae377
  +Save
• A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England
  Therapeutic advances in neurological disorders 2024 DOI: 10.1177/17562864241237495
  +Save
• Susac syndrome
  Journal of Neurology 2023 DOI: 10.1007/s00415-023-11891-z
  +Save
• Seasonal variation and temporal relationship to the COVID-19 pandemic of NMDA receptor antibody results
  Journal of Neurology 2023 DOI: 10.1007/s00415-023-11917-6
  +Save
• Autoantibody-mediated neurological diseases
  Medicine 2023 DOI: 10.1016/j.mpmed.2023.05.007
  +Save
• Quantitative Assessment of Response to Long‐Term Treatment with Intravenous Immunoglobulin in Patients with Stiff Person Syndrome
  Movement Disorders Clinical Practice 2021 DOI: 10.1002/mdc3.13261
  +Save
• CASPR2 antibody-related movement disorders
  Journal of Neurology 2021 DOI: 10.1007/s00415-020-10357-w
  +Save
• Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension
  Neurology 2021 DOI: 10.1212/WNL.0000000000011207
  +Save
• COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
  The Lancet Neurology 2020 DOI: 10.1016/S1474-4422(20)30413-0
  +Save
• Consistent improvement with eculizumab across muscle groups in myasthenia gravis
  Annals of Clinical and Translational Neurology 2020 DOI: 10.1002/acn3.51121
  +Save
• 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab
  Journal of Neurology 2020 DOI: 10.1007/s00415-020-09770-y
  +Save
• Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
  Journal of the Neurological Sciences 2020 DOI: 10.1016/j.jns.2020.116803
  +Save
• Human hippocampal CA3 damage disrupts both recent and remote episodic memories
  eLife 2020 DOI: 10.7554/eLife.41836
  +Save
• Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg
  Therapeutic advances in neurological disorders 2020 DOI: 10.1177/1756286420911784
  +Save
• Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis
  Journal of the Neurological Sciences 2019 DOI: 10.1016/j.jns.2019.08.004
  +Save
• Enlarged and Enhancing Optic Nerves in Advanced Glial Fibrillary Acidic Protein Meningoencephalomyelitis
  Journal of Neuro-Ophthalmology 2019 DOI: 10.1097/WNO.0000000000000842
  +Save
• Eculizumab improves fatigue in refractory generalized myasthenia gravis
  Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation 2019 DOI: 10.1007/s11136-019-02148-2
  +Save